Future perspectives with paracetamol;Nouvelles perspectives avec le paracétamol

Drugs

Volumn 63, Issue SPEC. ISS. 2, 2003, Pages 51-56

  Prescott, Laune F ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; NON PRESCRIPTION DRUG; PARACETAMOL; PROSTAGLANDIN SYNTHASE;

ANALGESIC ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CATARACT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MECHANISM; DRUG MISUSE; DRUG OVERDOSE; FEVER; HUMAN; LIVER FAILURE; LIVER TOXICITY; POSTOPERATIVE ANALGESIA; REVIEW;

EID: 0142209116     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363992-00008     Document Type: Review

References (21)

1. Grattan T, Hickman R, Darby-Dowman A, et al. A five way crossover human volunteer study to compare the pharmacokinetics of paracetamol following oral administration of two commercially available paracetamol tablets and three development tablets containing paracetamol in combination with sodium bicarbonate or calcium carbonate. Eur J Pharm Biopharm 2000; 49: 225- 9
2. Rygnestad T, Zahlsen K, Samdal FA. Absorption of effervescent paracetamol tablets relative to ordinary paracetamol tablets in healthy volunteers. Eur J Clin Pharmacol 2000; 56: 141-3
3. Moller PL, Norholt SE, Ganry HE, et al. Time to onset of analgesia and analgesic efficacy of effervescent acetaminophen 1000 mg compared to tablet acetaminophen 1000 mg in postoperative dental pain: a single-dose, double-blind, randomized, placebo-controlled study. J Clin Pharmacol 2000; 40: 370-8
4. Douglas DR, Sholar JB, Smilkstein MJ. A pharmacokinetic comparison of acetaminophen products (Tylenol extended relief vs regular Tylenol). Acad Emerg Med 1996; 3: 740-4
5. Bannwarth B, Netter P, Lapicque F, et al. Plasma and cerebrospinal fluid concentrations of paracetamol after a single intravenous dose of propacetamol. Br J Clin Pharmacol 1992; 34: 79-81
6. Granry JC, Rod B, Monrigal JP, et al. The analgesic efficacy of an injectable prodrug of acetaminophen in children after orthopaedic surgery. Paediatr Anaesth 1997; 7: 445-9
7. Varrassi G, Marinangeli F, Agrò F, et al. A double-blinded evaluation of propacetamol versus ketorolac in combination with patient-controlled analgesia morphine: analgesic efficacy and tolerability after gynecologic surgery. Anesth Analg 1999; 88: 611-16
8. Van Dyke K, Sacks M, Qazi N. A new screening method to detect water-soluble antioxidants: acetaminophen (Tylenol) and other phenols react as antioxidants and destroy peroxynitrite-based luminol-dependent chemiluminescence. J Bioluminesc Chemiluminesc 1998; 13: 339-48
9. Nenseter MS, Halvorsen B, Rosvold O, et al. Paracetamol inhibits copper ion-induced, azo compound-initiated, and mononuclear cell-mediated oxidative modification of LDL. Arterioscler Thromb Vase Biol 1995; 15: 1338-44
10. Al Rayyes O, Ahrén B, Florén C-H. Enhancement of low density lipoprotein catabolism by non-steroidal antiinflammatory drugs in cultured HepG2 cells. Eur J Pharmacol 1999; 372: 311-18
11. Taylor AA, Raya JL, Blatzheim LP, et al. Acetaminophen inhibits both chemical- and cell-mediated human LDL oxidation in vivo and in vitro. Arch Pharmacol 1999; 358 Suppl 2: R468
12. Smith CV, Rogers LK, Raya JL, et al. Antioxidant and antiatherogenic effects of low dose acetaminophen in hypercholesterolemic rabbits in vivo. Pediatr Res 2000; 47 Suppl 2: 473A
13. Rogers LK, Taylor AA, Raya JL, et al. Inhibition of fatty streak formation and lipid oxidation by low doses of acetaminophen in hypercholesterolemic rabbits. Toxicologist 2000; 54: 348
14. Rogers LK, Taylor AA, Raya JL, et al. Acetaminophen lowers fatty streak formation and lipid oxidation in hypercholesterolemic rabbits. Free Radic Biol Med 1999; 27 Suppl 1: S108
15. Gianotti A. LDL cholesterol oxidation and acetaminophen. Eur J Lab Med 1999; 7: 99
16. Merlo J, Broms K, Lindblad U, et al. Association of outpatient utilisation of non-steroidal anti-inflammatory drugs and hospitalised heart failure in the entire Swedish population. Eur J Clin Pharmacol 2001; 57: 71-5
17. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. Arch Intern Med 2000; 160: 777-84
18. Harding JJ, van Heyningen R. Drugs, including alcohol, that act as risk factors for cataract, and possible protection against cataract by aspirin-like analgesics and cyclopenthiazide. Br J Ophthalmol 1988; 72: 809-14
19. Harding JJ, Egerton M, Harding R. Protection against cataract by aspirin, paracetamol and ibuprofen. Acta Ophthalmol 1989; 67: 518-24
20. Shyadehi AZ, Harding JJ. Investigations of ibuprofen and paracetamol binding to lens proteins to explore their protective role against cataract. Biochem Pharmacol 1991; 42: 2077-84
21. Bazzi MD, Rabbani N, Duhaiman AS. Inhibition of camel lens zeta-crystallin by aspirin and aspirin-like analgesics. Int J Biochem Cell Biol 2002; 34: 70-7